IAI SPECIAL EDITION: Drug therapy for COVID-19 inpatients in West Nusa Tenggara hospital
DOI:
https://doi.org/10.46542/pe.2022.222.180183Keywords:
COVID-19, Hospital, Inpatient, TherapyAbstract
Background: COVID-19 represents an unprecedented challenge to the world. Various attempts have been made to overcome COVID-19, including employing multiple drug therapies.
Objective: This study was conducted to describe the drug therapy of COVID-19 inpatients at the West Nusa Tenggara Hospital in 2020.
Methods: Observation of 102 patients was conducted retrospectively. Data collection was performed by analysing medical records.
Results: A total of 62 out of the 102 patients (60.8%) were hospitalised more than four weeks. 57 patients (55.9%) received antivirus therapy with Oseltamivir and 47 patients (46.1%) recieved azithromycin as adjuvant antibiotic therapy. Most of the patients (63.7%) received vitamin C as an immunomodulator. A small number of patients received other supportive therapies recommended to decrease the symptoms of COVID-19. The most frequent administered therapies for COVID-19 patients hospitalised at the West Nusa Tenggara Hospital are antivirals, antibiotics, and immunomodulatory.
Conclusion: The findings provide an overview of therapy use for COVID-19 inpatients in West Nusa Tenggara Hospital. There is a need to assess the effectiveness of the therapy to promote safe and effective use of drugs for COVID-19 patients in the future.
References
Bonanad, C., García-blas, S., Tarazona-santabalbina, F., Sanchis, J., Bertomeu-gonzález, V., Fácila, L., Ariza, A., Núñez, J., & Cordero, A. (2020). The Effect of Age on Mortality in Patients With COVID-19 : A Meta-Analysis With 611 , 583 Subjects. Journal of the American Medical Directors Association, 21(7), 915–918. https://doi.org/10.1016/j.jamda.2020.05.045
DISKOMINFOTIK NTB. (2021). Data COVID-19 NTB (online). Available from: https://corona.ntbprov.go.id/
Donsu, Y.C., & Hasmono, D. (2020). Tinjauan Azitromisin Pada Penyakit Virus Korona 2019 ( COVID-19 ) Review of Azithromycin for Coronavirus Disease 2019 ( COVID-19 ). PHARMACON Jurnal Ilmiah Farmasi, 17(2), 133–147
Id, S. W., Xue, L., Legido-quigley, H., Khan, M., & Wu, H. (2020). Understanding factors influencing the length of hospital stay among non-severe COVID-19 patients : A retrospective cohort study in a Fangcang shelter hospital. 1–14. https://doi.org/10.1371/journal.pone.0240959
Maruta, H., & He, H. (2020). PAK1-blockers: Potential Therapeutics against COVID-19. Medicine in Drug Discovery, 6, 100039. https://doi.org/10.1016/j.medidd.2020.100039
Mira, A., Dewi, C., Dagradi, E.M., & Wibowo, P. (2021). The effect of high dose vitamin c (ascorbic acid) on proinflammatory cytokines in COVID-19, 5(01), 46–50.
Pinzón, M.A., Ortiz, S., Holguín, H., Betancur, J.F., Arango, D.C., Laniado, H., Arias, C.A., Munõz, B., Quiceno, J., Jaramillo, D., & Ramirez, Z. (2021). Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia. PLoS ONE, 16(5 May), 1–13. https://doi.org/10.1371/journal.pone.0252057
Pivonello, R., Auriemma, S., & Pivonello, C. (2020). Sex Disparities in COVID-19 Severity and Outcome : Are Men Weaker or Women Stronger ? Neuroendocrinology, 1–20. https://doi.org/10.1159/000513346
Ramatillah, D.L. & Isnaini, S. (2021) Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta, PLoS ONE, 16(4 April), 1–11. https://doi.org/10.1371/journal.pone.0250147
Smith, T., Bushek, J., & Prosser, T. (2020). COVID-19 Drug Therapy Highlights : Antimicrobials with potential activity against SARS-CoV-2 : Clinical Drug Information, Cdc, 1–21
Sultana, J., Maria, P., Salvatore, C., Gabriele, C., Gaetano, P., & Trifirò, G. (2020). Azithromycin in COVID ‑ 19 Patients : Pharmacological Mechanism , Clinical Evidence and Prescribing Guidelines. Drug Safety, https://doi.org/10.1007/s40264-020-00976-7
Susen, S., Susen, S., Tacquard, C.A., Godon, A., Mansour, A., Garrigue, D., Nguyen, P., Godier, A., Testa, S., Levy, J.H., Albaladejo, P., & Gruel, Y. (2020). Prevention of thrombotic risk in hospitalised patients with COVID-19 and hemostasis monitoring. Critical Care, 24(1), 1–8. https://doi.org/10.1186/s13054-020-03000-7
Tan, Q., Duan, L., Ma, Y., Wu, F., Huang, Q., Mao, K., Xiao, W., Xia, H., Zhang, S., Zhou, E., Ma, P., Song, S., Li, Y., Zhao, Z., Sun, Y., Li, Z., & Geng, W. (2020). Is oseltamivir suitable for fighting against COVID-19 : In silico assessment, in vitro and retrospective study. Bioorganic Chemistry, 104(104257)
Thomas, S., Patel, D., Bittel, B., Wolski, K., Wang, Q., Kumar, A., Il’Giovine, Z.J., Mehra, R., McWilliams, C., Nissen, S.E., & Desai, M.Y. (2021). Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction among Ambulatory Patients with SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial. JAMA Network Open, 4(2), 1–10. https://doi.org/10.1001/jamanetworkopen.2021.0369
WHO (World Health Organization) (2021). WHO Coronavirus Disease (COVID-19) Dashboard (online). Available at: COVID-19 .who.int
Zhang, X.W., & Yap, Y. L. (2004). The 3D structure analysis of SARS-CoV S1 protein reveals a link to influenza virus neuraminidase and implications for drug and antibody discovery. Journal of Molecular Structure (Theochem), 681, 137–141. https://doi.org/10.1016/j.theochem.2004.04.065
